Cargando…

Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Ian F, Ismail, Ozama, Machhada, Asif, Colgan, Niall, Ohene, Yolanda, Nahavandi, Payam, Ahmed, Zeshan, Fisher, Alice, Meftah, Soraya, Murray, Tracey K, Ottersen, Ole P, Nagelhus, Erlend A, O’Neill, Michael J, Wells, Jack A, Lythgoe, Mark F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447521/
https://www.ncbi.nlm.nih.gov/pubmed/32705145
http://dx.doi.org/10.1093/brain/awaa179
_version_ 1783574318838448128
author Harrison, Ian F
Ismail, Ozama
Machhada, Asif
Colgan, Niall
Ohene, Yolanda
Nahavandi, Payam
Ahmed, Zeshan
Fisher, Alice
Meftah, Soraya
Murray, Tracey K
Ottersen, Ole P
Nagelhus, Erlend A
O’Neill, Michael J
Wells, Jack A
Lythgoe, Mark F
author_facet Harrison, Ian F
Ismail, Ozama
Machhada, Asif
Colgan, Niall
Ohene, Yolanda
Nahavandi, Payam
Ahmed, Zeshan
Fisher, Alice
Meftah, Soraya
Murray, Tracey K
Ottersen, Ole P
Nagelhus, Erlend A
O’Neill, Michael J
Wells, Jack A
Lythgoe, Mark F
author_sort Harrison, Ian F
collection PubMed
description The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike.
format Online
Article
Text
id pubmed-7447521
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74475212020-08-27 Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model Harrison, Ian F Ismail, Ozama Machhada, Asif Colgan, Niall Ohene, Yolanda Nahavandi, Payam Ahmed, Zeshan Fisher, Alice Meftah, Soraya Murray, Tracey K Ottersen, Ole P Nagelhus, Erlend A O’Neill, Michael J Wells, Jack A Lythgoe, Mark F Brain Original Articles The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike. Oxford University Press 2020-08 2020-07-23 /pmc/articles/PMC7447521/ /pubmed/32705145 http://dx.doi.org/10.1093/brain/awaa179 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Harrison, Ian F
Ismail, Ozama
Machhada, Asif
Colgan, Niall
Ohene, Yolanda
Nahavandi, Payam
Ahmed, Zeshan
Fisher, Alice
Meftah, Soraya
Murray, Tracey K
Ottersen, Ole P
Nagelhus, Erlend A
O’Neill, Michael J
Wells, Jack A
Lythgoe, Mark F
Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title_full Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title_fullStr Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title_full_unstemmed Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title_short Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model
title_sort impaired glymphatic function and clearance of tau in an alzheimer’s disease model
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447521/
https://www.ncbi.nlm.nih.gov/pubmed/32705145
http://dx.doi.org/10.1093/brain/awaa179
work_keys_str_mv AT harrisonianf impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT ismailozama impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT machhadaasif impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT colganniall impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT oheneyolanda impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT nahavandipayam impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT ahmedzeshan impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT fisheralice impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT meftahsoraya impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT murraytraceyk impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT ottersenolep impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT nagelhuserlenda impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT oneillmichaelj impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT wellsjacka impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel
AT lythgoemarkf impairedglymphaticfunctionandclearanceoftauinanalzheimersdiseasemodel